Determining Value for Innovation and Setting Prices

Determining Value for Innovation and Setting Prices

PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and 1 Saloni Tanna Eduardo Sabat Joyce Wilson Ann Wilberforce Marjolein Willemen Monique Renevier Lisa Greenough Kathy Hurst Objectives of Priority Medicines Project Provide a methodology for identifying pharmaceutical gaps from a public health perspective, for Europe and the World . Provide a public-health based pharmaceutical R&D agenda for use by the EU in the 7th

Framework Programme, Good public policy should spend public funds on areas of greatest public needs 2 Generating a Preliminary List of Diseases and Gaps Cochrane database of systematic reviews Clinical efficacy Burden of disease ranking EU10, EU25 The world (including EU25) Projections and trends PRELIMINARY LIST OF PRIORITY DISEASES AND GAPS IN DEPTH REVIEWS OF PRELIMINARY LIST OF DISEASES AND GAPS FINAL REPORT 3 Social solidarity

Pharmaceutical "Gap" Treatment of ACUTE Stroke (Outcome: Survival at end of treatment or follow-up, unless noted otherwise) 1.8 Various excitatory nerve amino acid antagonists 1.6 Ion channel ,modulators Antiplatelet therapies Fibrinogen depleting agents Glycerol Relative Risk (<1 favors placebo) 1.4 1.2 1 0.8

0.6 0.4 0.2 0 4 NMDA antagonists Gangliosides Streptokinase urokinase ( 7 days) Example of an absent pharmaceutical gap Secondary prevention of occlusive event (Stroke/MI) with antiplatelet therapy 2.5 Picotamide Relative risk (<1 favours placebo) 2

Suloctidil Ticlopidine 1.5 Prior MI Prior MI Prior stroke Aspirin any dose Dipyridamole All trials 1 Sulfinpyrazole 0.5 0 5 .

. . . . . . . . . . . "Commonality of interest" EUROPE 10% ??

?? 8% 6% 4% THE WORLD 2% 0 2% 4% 6% Antimicrobial Resistance Pandemic Influenza Ischaemic Heart Disease Diabetes Mellitus Cancer* Acute Stroke** HIV/AIDS Tuberculosis Neglected Diseases***

Malaria Alzheimer and other dementias Osteoarthritis COPD Alcohol use disorders 6 Unipolar depression Maternal hemorrhage 8% 10% ?? ?? Special Needs for Women, Children, and the Elderly All groups neglected in drug development Complicated by different physiology & metabolism Recent improvements in situation of women and children Considerable gaps remain for the elderly who use the most medicines 7

Determining Value for Innovation and Setting Prices Octavia Quintana Trias, DG Research "How do you value innovation? Special thanks to David Henry, Sue Hill & Danielle Lang 8 Mr Gnter VERHEUGEN (Enterprise and Industry) September 2004 "As for the economic aspects of medicinal products, the Commission could, following deliberations on pricing and reimbursement methods, play a part in developing alternative approaches aimed at promoting innovation and making it financially rewarding. Similarly, questions concerning national procedures for determining the therapeutic value of new medicinal products must also be tackled." 9 The Problem European government have a dual role as purchasers and in promoting innovation All OECD countries except USA regulate pharmaceutical prices using up to five different

methods (Jacobzone) Price setting process is unpredictable for level and time to a decision (Black box) Pharmaceuticals are among the most highly regulated products Pharmaceuticals are only a small proportion of total health care costs in developed countries 10 www.pmprb-cepmb.gc.ca/symposium2002/ present/Jacobzone-Oct7-OECD/ Delays From Pricing And/ Or Reimbursement Application To Reimbursement (EFPI A Data) 90 days 180 days Belgium Greece Portugal France Austria Finland Italy Norway Spain Netherlands Switzerland Sweden Denmark Ireland Germany

UK 0 11 Increasing overall delay Pricing Reimbursement P&R 100 200 300 400 500 Publication 600 700

800 (Days) In Belgium - until January 2002, the tr ansparency commission pr ocess had to be conducted before a company could apply for reimbursement of a given product. In France, only ambulatory care products have been included in this analysis. In Italy and Sweden the pricing and/or reimbursement procedure can start as soon as CPMP opinion is available (for centrally appr oved medicines). This analysis does not reflect the impact of recent r eforms in Italy. In Spain anecdotal evidence suggests that delays have incr eased recently. In Switzerland a more comprehensive study concer ning 191 files shows an average delay over 180 days. Finland has a two-tier reimbursement system, with a slower process for treatments of chr onic diseases (reimbursed at 75%) and serious or life-threatening diseases, and a faster one for acute diseases. Delays shown in this study do not reflect this distinction, and actual pricing and reimbursement delays are typically longer for medicines in the 75%/100% reimbursement categories Differential Pricing and Parallel Trade Differential pricing already occurs for many consumer products For pharmaceuticals dramatic differences already exist between countries for vaccines, oral contraceptives, antimalarials and ARVs Economic theory indicates that where the true marginal costs of a product are low, price discrimination will increase the total revenue of a company, so long as parallel trade can be minimized A number of technical solutions have been proposed to limit pharmaceutical parallel trade, such as unique presentation and country-specific labelling and packaging measures 12

Parallel Trade - The Evidence Panos Kanavos (LSE) 2003 Examined 19 top-selling drugs in six Northern European "destination countries" of imports -- account for almost a quarter of all prescription drug sales in Europe. Combined sales of reimported versions of these drugs saved 0.3 percent to 3.6 % of their annual drug budgets, or slightly more than $100 million. Savings were not passed on to consumers Drug prices in Northern and Southern Europe did not become more similar. The biggest gains from selling imported drugs (46% of the sales of all products studied) went straight to the repackagers. 13 http://www.washingtonpost.com/wp-dyn/articles/A60984-2004Sep29.html Spreading the Burden of Drug Development Costs and Valuing new medicines Rewarding innovation is a key aspect of pricing i.e. real innovation should be rewarded! Pricing should reflect ability to pay possibly measured as GNI per capita Pharmaco-economics already provides the

methods for reactive price setting and could be used proactively 14 Proposed Method (Henry 2002) The World Bank has suggested that health care interventions may be considered cost-effective if they buy a year of healthy life for less than the national average per capita GNI The method proposed for further evaluation is based on GNI per capita and efficacy measures 15 Indicative prices of highly active antiretrovirals (HAART) and a new hypothetical regimen in countries of variable wealth 30000 United Kingdom France Italy Spain 20000 15000 Slovenia

Czech Republic 10000 Latvia 5000 Mali Kazakhstan Philippines Georgia India Russia Indicative price existing treatment 26076 23225 15000 20000 25000 Per Capita GNI $US 16 22783

19831 15627 12620 5000 10881 6199 4921 3744 3477 2500 2566 2557 2000 2401

2125 1959 1000 1637 1214 993 855 500 763 607 487 200 441 294 0

267 Indicative price $US 25000 Indicative price new drug Indicative prices of existing antidepressant treatment and a hypothetical new medicine with greater efficacy $6,000 United Kingdom France $5,000 Indicative Price $US Italy $4,000 Singapore $3,000 $2,000 Spain

$1,000 Mali India Czech Republic Slovenia Greece Latvia $0 0 5 10 15 20 Per Capita GNI $000US 17 Indicative price existing treatm ent

Indicative price new drug 25 30 Conclusions (1) Possible to incorporate measures of clinical performance and national wealth in determining indicative prices for pharmaceuticals. Does not mean that the indicative price is necessarily the right price, the lowest possible price or an affordable price. No guarantee that manufacturers will be interested in manufacturing products on this basis. 18 Conclusions (2) A more predictable system that encourages medicines development and achieves affordability of access in countries of variable wealth requires reconsideration of current policies towards parallel trade. Parallel imports tend to favour high-income countries, which can benefit from the prices paid in lower-income countries. May hurt lower income countries. Reference pricing encourages higher prices for poorer countries

Any inhibition of parallel trade conflicts with European law, which highlights the need for a wide debate & research on these issues. 19 Reviewer Comments The model is theoretically interesting but impractical. There is such a strong commitment to the ideal of a European Common Market that any restrictions on parallel trade would be unacceptable. Technical requirements for such an approach would be impossible to undertake proactively. 20 Final Summary If rewarding innovation is one of the intended effects of reimbursement policies, then setting prices related to the level of clinical efficacy and the national wealth as measured by GNI per capita would be a logical and transparent approach. A researchable topic! 21

Recently Viewed Presentations

  • Logistics Information Management Course 2005

    Logistics Information Management Course 2005

    Unique Identification (UID) Integrated situational awareness of people, places, and things RFID Tracking Welcome on behalf of the Defense Logistics Information Service (DLIS) to this 2004 session of The Logistics Information Management Course for International Logisticians. Unofficially, we use the...
  • Michigan Public School Employees Retirement System

    Michigan Public School Employees Retirement System

    On June 7, 2016, the Michigan Court of Appeals ruled on Public Act 75 of 2010 and the 3% healthcare contributions that are being held in escrow for public school retirees. The court remanded the ruling back to the trial...
  • EEE161 Lab Plan - California State University, Sacramento

    EEE161 Lab Plan - California State University, Sacramento

    Last EEE161 Lab in the Antenna Lab, Santa Clara 1119 D 12/4 & 12/5 . Each group gets ½ hour for impedance and ½ hour for patterns. 1. QRH group goes first with patterns; impedance not needed 12:00
  • How to Publish with IEEE

    How to Publish with IEEE

    The IEEE Style Manual provides editorial guidelines for all IEEE transactions, periodicals, and letters. There is also a tool for validating references, an IEEE PDF Checker, and the IEEE Editing Assistance program to refine the use of English in your...
  • Presentation - Kentucky

    Presentation - Kentucky

    KDE is seeking a vendor to assist with answer change/erasure analysis, timing and examination trend analysis, similarity analysis, unusual score gains and drops, and additional analysis. ... (CD player or computer with a CD drive needed to listen . ......
  • Jupiter and Saturns Satellites of Fire and Ice

    Jupiter and Saturns Satellites of Fire and Ice

    What could account for differences between the inner and outer Galilean satellites? Why does Io have active volcanoes? How does Io's volcanic activity differ from that on Earth? How does Io act like an electric generator? What is the evidence...
  • HOW TO PROTECT SOFTWARE - Bilkent University

    HOW TO PROTECT SOFTWARE - Bilkent University

    The Bern Convention provides this for all the countries that are members of the convention. They will automatically be protected in every country where computer programs are created as part of literary works.
  • Diapositive 1 - Créer un blog gratuitement sur Unblog.fr

    Diapositive 1 - Créer un blog gratuitement sur Unblog.fr

    Amblyopie :Signe de la Toupie L'attention de l'enfant est attiré par un objet : du côté non amblyope Seul les yeux tournent pour fixer l'objet du côté de l'œil amblyope l'enfant doit tourner la tête pour le fixer avec l'autre...